BR112021026214A2 - Método para tratamento de fibrose pulmonar idiopática - Google Patents
Método para tratamento de fibrose pulmonar idiopáticaInfo
- Publication number
- BR112021026214A2 BR112021026214A2 BR112021026214A BR112021026214A BR112021026214A2 BR 112021026214 A2 BR112021026214 A2 BR 112021026214A2 BR 112021026214 A BR112021026214 A BR 112021026214A BR 112021026214 A BR112021026214 A BR 112021026214A BR 112021026214 A2 BR112021026214 A2 BR 112021026214A2
- Authority
- BR
- Brazil
- Prior art keywords
- pulmonary fibrosis
- idiopathic pulmonary
- treatment
- polymorph
- stereoisomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019092675 | 2019-06-25 | ||
| PCT/CN2020/097881 WO2020259528A1 (zh) | 2019-06-25 | 2020-06-24 | 治疗特发性肺纤维化的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021026214A2 true BR112021026214A2 (pt) | 2022-02-15 |
Family
ID=74061495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021026214A BR112021026214A2 (pt) | 2019-06-25 | 2020-06-24 | Método para tratamento de fibrose pulmonar idiopática |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12582653B2 (https=) |
| EP (1) | EP3992183A4 (https=) |
| JP (1) | JP7615061B2 (https=) |
| KR (1) | KR20220029681A (https=) |
| CN (2) | CN119868365A (https=) |
| AU (1) | AU2020305979B2 (https=) |
| BR (1) | BR112021026214A2 (https=) |
| CA (1) | CA3144113A1 (https=) |
| IL (1) | IL289192A (https=) |
| TW (1) | TWI804743B (https=) |
| WO (1) | WO2020259528A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230061444A (ko) * | 2020-08-31 | 2023-05-08 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Rho-연관 단백질 인산화효소 억제제의 염, 염의 고체 형태, 이의 제조 방법 및 이의 용도 |
| WO2022178420A1 (en) * | 2021-02-22 | 2022-08-25 | Graviton Bioscience Bv | Rock2 inhibitor for the treatment of viral infection |
| NO346587B1 (en) * | 2021-06-02 | 2022-10-17 | Axichem Ab | Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis |
| TW202327608A (zh) * | 2021-09-17 | 2023-07-16 | 北京泰德製藥股份有限公司 | 治療病毒感染的方法 |
| EP4393917A4 (en) * | 2021-09-18 | 2025-09-10 | Beijing Tide Pharmaceutical Co Ltd | SOLID FORM OF A RHO-ASSOCIATED PROTEIN KINASE INHIBITOR OR SOLVATE THEREOF, METHOD OF PREPARATION AND USE THEREOF |
| CN118215468A (zh) * | 2021-11-16 | 2024-06-18 | 北京泰德制药股份有限公司 | 一种rock2抑制剂的纳米晶制剂及其制备方法 |
| CN116425745B (zh) * | 2022-01-13 | 2025-06-13 | 武汉朗来科技发展有限公司 | 一种rock抑制剂的盐及盐的晶型、组合物和药物用途 |
| CN120035442A (zh) * | 2022-10-13 | 2025-05-23 | 北京泰德制药股份有限公司 | 治疗尘肺病的方法 |
| WO2025017500A1 (en) | 2023-07-17 | 2025-01-23 | Graviton Bioscience Bv | Formulations of rock2 inhibitors for cns disorders |
| WO2025017499A1 (en) | 2023-07-17 | 2025-01-23 | Graviton Bioscience Bv | Formulations and uses of rock2 inhibitors for als |
| WO2025069008A1 (en) | 2023-09-28 | 2025-04-03 | Graviton Bioscience Bv | Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors |
| WO2025069009A1 (en) | 2023-09-29 | 2025-04-03 | Graviton Bioscience Bv | Rock2 inhibitors in the treatment of obesity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3262041A4 (en) | 2015-02-27 | 2018-08-01 | Lycera Corporation | Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease |
| TWI800498B (zh) * | 2016-12-21 | 2023-05-01 | 義大利商吉斯藥品公司 | 作為Rho-激酶抑制劑之雙環二氫嘧啶-羧醯胺衍生物 |
| JP7311228B2 (ja) * | 2017-06-30 | 2023-07-19 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用 |
| KR102563325B1 (ko) | 2017-06-30 | 2023-08-03 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도 |
-
2020
- 2020-06-24 EP EP20833444.1A patent/EP3992183A4/en active Pending
- 2020-06-24 TW TW109121568A patent/TWI804743B/zh active
- 2020-06-24 WO PCT/CN2020/097881 patent/WO2020259528A1/zh not_active Ceased
- 2020-06-24 AU AU2020305979A patent/AU2020305979B2/en active Active
- 2020-06-24 US US17/621,719 patent/US12582653B2/en active Active
- 2020-06-24 KR KR1020227002368A patent/KR20220029681A/ko active Pending
- 2020-06-24 CN CN202510159677.8A patent/CN119868365A/zh active Pending
- 2020-06-24 CN CN202080045478.XA patent/CN114026072A/zh active Pending
- 2020-06-24 JP JP2021576479A patent/JP7615061B2/ja active Active
- 2020-06-24 BR BR112021026214A patent/BR112021026214A2/pt unknown
- 2020-06-24 CA CA3144113A patent/CA3144113A1/en active Pending
-
2021
- 2021-12-21 IL IL289192A patent/IL289192A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3992183A1 (en) | 2022-05-04 |
| JP2022539329A (ja) | 2022-09-08 |
| US12582653B2 (en) | 2026-03-24 |
| TW202114679A (zh) | 2021-04-16 |
| CA3144113A1 (en) | 2020-12-30 |
| TWI804743B (zh) | 2023-06-11 |
| AU2020305979A1 (en) | 2022-02-17 |
| EP3992183A4 (en) | 2023-06-21 |
| KR20220029681A (ko) | 2022-03-08 |
| JP7615061B2 (ja) | 2025-01-16 |
| CN114026072A (zh) | 2022-02-08 |
| CN119868365A (zh) | 2025-04-25 |
| US20220233538A1 (en) | 2022-07-28 |
| WO2020259528A1 (zh) | 2020-12-30 |
| AU2020305979B2 (en) | 2026-04-23 |
| IL289192A (en) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021026214A2 (pt) | Método para tratamento de fibrose pulmonar idiopática | |
| BR112021017354A2 (pt) | Método para o tratamento de doença hepática adiposa e/ou esteatoepatite | |
| CR20220281A (es) | Derivados de pirazolilo útiles como agentes anti-cancerígenos | |
| BR112021014525A8 (pt) | Inibidor de jak e método de preparação do mesmo | |
| MX2021009806A (es) | Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos. | |
| EP4292588A3 (en) | Administration of deuterated cftr potentiators | |
| MX2017010477A (es) | Compuestos triciclicos y usos de los mismos en medicina. | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| NZ721645A (en) | Compounds for use as gpr120 agonists | |
| BR112015020600A2 (pt) | composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição | |
| WO2016085939A3 (en) | Compounds and methods of treating ocular disorders | |
| MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
| MY209754A (en) | Amide derivative and preparation method therefore and use thereof in medicine | |
| BR112013028095A2 (pt) | inibidores de csf-1r para o tratamento de tumores cerebrais | |
| BR112016024473A2 (pt) | composto, composição farmacêutica, e, método para tratamento de uma doença e/ou condição | |
| MX2023001671A (es) | Procedimiento y compuesto para su uso en el tratamiento y/o prevención de la netosis. | |
| PH12017500029A1 (en) | 4,5-dihydroisoxazole derivatives as nampt inhibitors | |
| WO2016168553A8 (en) | Deuterated obeticholic acid | |
| MX384293B (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefálica | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| EA201891682A1 (ru) | Производное азациклического амида, способ его получения и фармацевтическое применение | |
| BR112022002107A2 (pt) | Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo | |
| CL2022001516A1 (es) | Compuesto y composición como inhibidor de quinasa del receptor pdgf | |
| MX2022000154A (es) | Alfa-amino esteres de derivado de hidroxipropiltiazolidin carboxamida, y formas de sales y polimorfos cristalinos de estos. | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |